We enter the cathedral of medicine with a specific architecture of the soul: high ambition, perfectionism…
Category: Trending
Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS Business
Delivers Letter to STIM Board Outlining Potential 5-7x Upside for Shareholders Inherent in Sale of TMS…
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor). IDE161 (PARG)…
Oasis Aesthetics & Wellness Introduces Breakthrough Noninvasive Technologies for Brain Health, Facial Rejuvenation, and Body Sculpting
SUGAR LAND, Texas, March 26, 2026 /PRNewswire/ — Oasis Aesthetics & Wellness, an innovative health and…
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle…
Hartford HealthCare Announces Tender Offer for Outstanding Debt Securities
Hartford HealthCare Corporation (the “Corporation“) today announced that it has commenced a tender offer to purchase…
Webinar Series: Mastering risk adjustment essentials in 2026
Risk adjustment is a strategic, constantly evolving field at the heart of healthcare transformation, and 2026…
Best Creatine for Men (2026): iHerb Recognized for the Widest Selection of Creatine Supplements by Expert Consumers
NEW YORK, Jan. 26, 2026 /PRNewswire/ — Expert Consumers has recognized iHerb for offering the widest…
Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis
Elanco’s second dermatology product approval in less than 18 months in the estimated $1.3 billion U.S.…
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
SAN DIEGO, Nov. 25, 2025 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical…